RecruitingPhase 2NCT07032727
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Sponsor
M.D. Anderson Cancer Center
Enrollment
68 participants
Start Date
Sep 12, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Cladribine (CLAD), a drug called Cytarabine, and others for people with idh1-mutated malignancies, mutations, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOlutasidenib
Given by po
DRUGCladribine (CLAD)
Given by IV
DRUGVenetoclax
Given by po
DRUGGilteritinib
Given by po
DRUGRuxolitinib
Given by po
DRUGCytarabine
Given SQ
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07032727
Related Trials
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
NCT0700668819 locations
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
NCT063565841 location
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
NCT070409561 location
Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
NCT074368451 location
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
NCT072199401 location